4d Molecular Therapeutics, INC 8-K filings

4D Molecular Therapeutics announced positive clinical data across multiple programs and a successful $300 million follow-on offering, extending their operational runway into the first half of 2027.

4D Molecular Therapeutics successfully completed a public offering of common stock and pre-funded warrants, raising approximately $281.4 million in net proceeds.